RNXT RenovoRx Corp: רווח נקי למניה אחת בשנים עשר החודשים האחרונים

לוגו של חברה ציבורית RenovoRx Inc (RNXT)

RenovoRx, Inc. (RNXT) is a reputable player in oncology that developed the TransAxial system for precision drug delivery. However, geopolitical tensions are hindering global testing and the supply of electronics for therapy. The stock price retrospective on GURU.Markets shows an EPS TTM of 12.60. The business relies on an internal production cycle, which makes the demand for these biotechnologies resilient to any economic downturns.

רווח נקי למניה (EPS TTM) RenovoRx, Inc. (RNXT): לתקופה 11.02.2024 - 17.11.2026

RenovoRx, Inc. - פילוחים אנליטיים ומדדי מפתח (RNXT)

- מחיר מניה ומחיר יעד קונצנזוס:
ניתוח ראשוני של החברה:RenovoRx RNXT
מוצר המיוצר על ידי RenovoRx Corporation

RenovoRx, Inc. (RNXT), which invests in high-tech AI-driven chemotherapy delivery R&D systems, is currently in an intensive development stage where profits are often volatile. By analyzing the 12-month YoY earnings per share (EPS) growth rate, investors assess net income dynamics adjusted for seasonality and one-time subsidies, allowing them to filter out market noise and determine the real fundamental momentum of this venture asset.